Summary & Overview
CPT 0565U: Plasma Methylation Assay for Hepatocellular Carcinoma
CPT code 0565U designates the EarlyDx MethylScan™ HCC proprietary laboratory assay, a plasma-based next-generation sequencing test that analyzes 6,626 methylation sites in cell-free DNA to detect a hepatocellular carcinoma (HCC) signal. As a PLA code, 0565U applies only to the single named test produced by EarlyDiagnostics Laboratory, making it a precise billing identifier for payers and providers managing novel molecular diagnostics. Nationally, methylation-based liquid biopsies are an emerging tool in oncology detection and surveillance, and clear coding supports claims processing, utilization tracking, and coverage policy development.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise context on the clinical purpose of the assay, typical sites of service, and payer relevance for molecular diagnostic billing. The publication also outlines expected benchmarks and policy considerations relevant to proprietary next-generation sequencing assays: coding specificity for PLA codes, payer coverage patterns for novel diagnostics, and implications for test ordering and lab-only services. Data not available in the input is noted where applicable, and the content focuses on national implications rather than state-specific rules.
Billing Code Overview
CPT code 0565U is a Proprietary Laboratory Analyses (PLA) code assigned exclusively to the EarlyDx MethylScan™ HCC assay performed by EarlyDiagnostics Laboratory. The test uses next-generation sequencing to evaluate methylation patterns in cell-free DNA from plasma, assessing 6,626 epigenetic alterations associated with hepatocellular carcinoma. An algorithmic interpretation reports a binary result: cancer signal detected or cancer signal not detected.
Service type: Laboratory — molecular pathology / circulating tumor DNA methylation assay
Typical site of service: Clinical laboratory testing from plasma specimens (ambulatory phlebotomy or outpatient collection sites)
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic liver disease or cirrhosis under surveillance for hepatocellular carcinoma (HCC) or a patient with risk factors for HCC (hepatitis B or C infection, nonalcoholic fatty liver disease with advanced fibrosis, hemochromatosis). A clinician orders the 0565U EarlyDx MethylScan™ HCC blood test when imaging (ultrasound, CT, or MRI) is inconclusive, when a less invasive adjunctive screening tool is desired, or as part of a comprehensive surveillance program for high‑risk patients. The clinical workflow: the provider documents medical necessity and risk factors in the chart, obtains informed consent for a plasma cell‑free DNA test, and places a blood draw order specifying the EarlyDiagnostics Laboratory test. A phlebotomy encounter is performed in an outpatient clinic, hospital outpatient lab, or commercial laboratory site; plasma is separated and shipped per the manufacturer’s specimen handling instructions to EarlyDiagnostics Laboratory. The laboratory performs next‑generation sequencing of cfDNA methylation signatures and applies the proprietary algorithm to report a binary cancer signal detected/not detected, with an interpretive report returned to the ordering provider. Results are reviewed in follow‑up visits to guide further diagnostic imaging, biopsy decisions, or continued surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (neutral) | Use when no special reporting modifier is required; standard reporting for the single proprietary test code. |